This industry session is organised independently from the scientific programme and is delivered by one of the ILCA AC2026 sponsors.
This year's Roche Symposium is titled The HCC Masterclass: From Pivotal Trials to Complex Cases. The aim of the symposium is to set the scene regarding the current treatment landscape in HCC, including recently published data from ASCO and ESMO GI and relevant real world data. Following this, the bulk of the session will deep dive into complex patient cases treated with atezolizumab + bevacizumab. This aims to educate and inform the audience about patients they may regularly see regularly in their clinics, supported by pivotal, exploratory, and real world data. Following this, we will allow sufficient time for a Q&A session to help engage the audience further.
